Share on LinkedInShare on LinkedIn

ARTICLE · 06 FEBRUARY 2026

FDA PreCheck Pilot Program Launches, Clearing A Smooth Path To Approval

Akin
Akin
Contributor
Akin

Akin

Akin is a global law firm with more than 1,100 lawyers and advisors who pride themselves on...

View firm profile
Explore more from Akin

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program.

United StatesFood, Drugs, Healthcare, Life Sciences

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply chain by making the review and inspection process more predictable for U.S.-based drug manufacturing facilities.

FDA will select an initial cohort of new pharmaceutical facilities and begin conducting PreCheck activities in 2026. A new manufacturing facility is one that is not an existing facility or an extension of an existing facility and has broken ground, will break ground by the proposal deadline or is in pre-operational development, intended to produce human drugs and/or biological products. Selection for inclusion in the program will be based on a facility's overall alignment with national priorities across several criteria, such as products to be manufactured, phase of facility development, timeline to producing pharmaceutical

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from